Clinical Trials Using Anti-CTLA-4 Monoclonal Antibody AGEN1884
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CTLA-4 Monoclonal Antibody AGEN1884. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.
Location: 11 locations
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1 / PD-L1 Inhibitor as Their Most Recent Therapy
This is an open-label, Phase 1 / 2, multicenter study to evaluate the safety, PK, and PD of an anti-CTLA-4 human monoclonal antibody (AGEN1884) in subjects with advanced or refractory cancer and in subjects who have progressed during treatment with a PD-1 / PD-L1 inhibitor as their most recent therapy. The phase 1 portion of the study has been completed; It enrolled adult subjects with refractory, advanced cancer in a 3+3 dose escalation cohort. The phase 2 portion consists of up to 60 patients who have progressed during treatment with an approved or investigational PD-1 / PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).
Location: 7 locations
AGEN1884 and AGEN2034 in Combination with Cisplatin and Gemcitabine for the Treatment of Muscle-invasive Bladder Cancer before Radical Cystectomy
This phase II trial investigates how well AGEN1884 and AGEN2034 work in combination with cisplatin and gemcitabine in treating patients with muscle-invasive bladder cancer before surgery that removes all of the bladder as well as nearby tissues and organs (radical cystectomy). AGEN1884 (a CTLA-4 blocking agent) and AGEN2034 (a PD-1 blocking agent) are a class of drugs called immune checkpoint inhibitors that may help the body's immune system attack the cancer and interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care treatment of muscle-invasive bladder cancer is chemotherapy followed by surgery and a cystectomy. Adding AGEN1884 and AGEN2034 to this standard treatment may improve the rate of the bladder cancer coming back.
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Doxorubicin, AGEN1884, and AGEN2034 for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial studies how well doxorubicin together with AGEN1884 and AGEN2034 work in treating patients with soft tissue sarcoma that has spread to other places in the body (advanced or metastatic). Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as AGEN1884 and AGEN2034, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin, AGEN1884, and AGEN2034 may work better in treating patients with soft tissue sarcoma compared to doxorubicin alone.
Location: University of Colorado, Denver, Colorado